Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Fiche publication
Date publication
octobre 2022
Journal
Clinical oncology (Royal College of Radiologists (Great Britain))
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROY Catherine, Dr VERNEREY Dewi
Tous les auteurs :
Le Roy C, Vernerey D, Evin C, Richard S, Crespel C, Samaille T, Le Tourneau C, Huguet F
Lien Pubmed
Résumé
The EXTREME regimen is the standard for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). However, many patients have a poor performance status and/or comorbidities, making them unfit for this regimen. We have treated them with carboplatin and cetuximab (simplified EXTREME regimen) since 2007. Our aim was to assess the efficacy and tolerance of this regimen in this frail population.
Mots clés
Carboplatin, EXTREME, cetuximab, elderly, head and neck squamous cell carcinoma, recurrent and/or metastatic
Référence
Clin Oncol (R Coll Radiol). 2022 10 4;: